AR052887A1 - Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa - Google Patents

Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa

Info

Publication number
AR052887A1
AR052887A1 ARP060100240A ARP060100240A AR052887A1 AR 052887 A1 AR052887 A1 AR 052887A1 AR P060100240 A ARP060100240 A AR P060100240A AR P060100240 A ARP060100240 A AR P060100240A AR 052887 A1 AR052887 A1 AR 052887A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
substituted
alkoxy
cycloalkyl
Prior art date
Application number
ARP060100240A
Other languages
English (en)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR052887A1 publication Critical patent/AR052887A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Composiciones farmacéuticas que comprenden a dichos compuestos y métodos para utilizar dichos compuestos para tratar o prevenir enfermedades o trastornos asociados con la actividad anormal o desregulada de la quinasa, particularmente enfermedades o trastornos que comprenden la activacion anormal de las quinasa Ab1, Bcr-Ab1, FGFR3, PDGFRbeta y b-Raf. Reivindicacion 1: Un compuesto de formula (1), en la que: n se selecciona del 0, 1, 2, 3 y 4; Y se selecciona de C, S, S(O) P y P(O); R1 se selecciona de alquilo C1-6, ariloC6-10-alquiloC0-4, heteroariloC5-10-alquiloC0-4, cicloalquiloC3-12-alquiloC0-4, heterocicloalquiloC3-8- alquiloC0-4 y -XNR7R8; en donde cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R1 se encuentra sustituido con 1-3 radicales independientemente seleccionados de halo, alquilo C1-6, alquiloC1-6 sustituido con halo, alcoxi C1-6, alcoxi C1-6 sustituido con halo, alquiltio C1-6, alquiltio C1-6 sustituido con halo, -XNR7R8, -XNR7XNR7R8, - XNR7R9, arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12 y heterocicloalquilo C3-8; en donde cualquier sustituyente arilo, heteroarilo, cicloalquilo o heterocicloalquilo en R1 puede estar opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados de halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alquilo C1-6 sustituido con hidroxi, alcoxi C1-6 y alcoxi C1-6 sustituido con halo; y en donde cualquier alquilo de R1 puede tener un metileno reemplazado con O; en donde X se selecciona independientemente de un enlace y alquileno C1-6; R7 y R8 seleccionan independientemente de hidrogeno y alquilo C1-6; en donde cualquier metileno de R7 y R8 se puede reemplazar con O; en donde R9 se selecciona de ariloC6- 10-alquiloC0-4, heteroariloC5-10-alquiloC0-4, cicloalquiloC3-12-alquiloC0-4 y heterocicloalquiloC3-8-alquiloC0-4; R2 se selecciona de hidrogeno y alquilo C1-6; R3 se selecciona de hidrogeno y alquilo C1-6; R4 se selecciona de halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6, alcoxi c1-6 sustituido con halo, alquiltio C1-6 y alquiltio C1-6 con halo; R5 se selecciona del hidrogeno y alquilo C1-6; y R6 se selecciona de arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12 y heterocicloalquilo C3-8; en donde dicho arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R6 se encuentra opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente de halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6, alcoxi C1-6 sustituido con halo, alquiltio C1-6, alquiltio C1-6 sustituido con halo, arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12, y heterocicloalquilo C3-8; en donde los sustituyentes arilo, heteroarilo, cicloalquilo o heterocicloalquilo en R6 pueden estar opcionalmente sustituidos con 1 a 3 radicales independientemente seleccionados de hidroxi, halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alquilo C1-6 sustituido con hidroxi, alcoxi C1-6 y alcoxi C1-6 sustituido con halo; y las sales, hidratos, solvatos, isomeros y profármacos farmacéuticamente aceptables de dichos compuestos.
ARP060100240A 2005-01-26 2006-01-23 Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa AR052887A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64760605P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
AR052887A1 true AR052887A1 (es) 2007-04-11

Family

ID=36740973

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100240A AR052887A1 (es) 2005-01-26 2006-01-23 Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa

Country Status (15)

Country Link
US (1) US20090105250A1 (es)
EP (1) EP1841431A4 (es)
JP (1) JP2008528585A (es)
KR (1) KR100919905B1 (es)
CN (1) CN101106990B (es)
AR (1) AR052887A1 (es)
AU (1) AU2006209183B2 (es)
BR (1) BRPI0607307A2 (es)
CA (1) CA2593803A1 (es)
GT (1) GT200600028A (es)
MX (1) MX2007008973A (es)
PE (1) PE20060877A1 (es)
RU (1) RU2368602C2 (es)
TW (1) TW200637547A (es)
WO (1) WO2006081172A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809614B1 (en) 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
PE20061394A1 (es) * 2005-03-15 2006-12-15 Bristol Myers Squibb Co Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
EP1904065A2 (en) * 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
CA2637172A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Pyridin-2-amine derivatives and their use as glucokinase activators
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
EP2078004B1 (en) 2006-10-31 2015-02-25 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
MX2009004786A (es) 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
JP2011513330A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
CA2716949A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9180127B2 (en) * 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011147764A1 (en) 2010-05-28 2011-12-01 N.V. Organon Thieno (2, 3b) pyrazine compounds as b - raf inhibitors
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
RU2011122942A (ru) * 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
MX2014002471A (es) * 2011-08-31 2014-03-27 Novartis Ag Combinaciones sinergicas de los inhibidores de p13k y mek.
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
RU2495430C1 (ru) * 2012-03-29 2013-10-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ оценки эффективности терапии хронического миелолейкоза
ES2605388T3 (es) * 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
RU2495427C1 (ru) * 2012-07-04 2013-10-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ прогнозирования ответа на химиотерапию при хроническом лимфолейкозе
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
SG10201700808UA (en) 2013-02-19 2017-02-27 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
AU2014361800B2 (en) 2013-12-13 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2016065138A1 (en) 2014-10-22 2016-04-28 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
TWI620748B (zh) * 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
WO2017147701A1 (en) 2016-03-01 2017-09-08 Ontario Institute For Cancer Research (Oicr) Inhibitors of wdr5 protein-protein binding
CN109195965B (zh) 2016-03-01 2022-07-26 普罗佩纶治疗公司 Wdr5蛋白质-蛋白质结合的抑制剂
WO2018183122A1 (en) * 2017-03-27 2018-10-04 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
WO2019202160A2 (en) 2018-04-20 2019-10-24 Iomx Therapeutics Ag A 5-thiazolecarboxamide kinase inhibitor and uses thereof
RU2768755C1 (ru) * 2018-05-09 2022-03-24 ЭлДжи КЕМ, ЛТД. Новое соединение, проявляющее ингибирующую активность в отношении энтеропептидазы
EP3643713A1 (en) 2018-10-23 2020-04-29 iOmx Therapeutics AG Heterocyclic kinase inhibitors and uses thereof
EP3901151A1 (en) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028907D1 (de) * 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis

Also Published As

Publication number Publication date
EP1841431A4 (en) 2009-12-09
CA2593803A1 (en) 2006-08-03
EP1841431A2 (en) 2007-10-10
PE20060877A1 (es) 2006-10-16
GT200600028A (es) 2006-10-18
WO2006081172A3 (en) 2006-09-14
KR20070095978A (ko) 2007-10-01
TW200637547A (en) 2006-11-01
US20090105250A1 (en) 2009-04-23
KR100919905B1 (ko) 2009-10-06
BRPI0607307A2 (pt) 2009-08-25
AU2006209183B2 (en) 2009-11-19
AU2006209183A1 (en) 2006-08-03
RU2007132262A (ru) 2009-03-10
JP2008528585A (ja) 2008-07-31
WO2006081172A2 (en) 2006-08-03
CN101106990B (zh) 2010-12-08
RU2368602C2 (ru) 2009-09-27
CN101106990A (zh) 2008-01-16
MX2007008973A (es) 2007-09-18

Similar Documents

Publication Publication Date Title
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
RU2012109233A (ru) Соединения как модуляторы тирозинкиназы
CR10915A (es) Compuestos y metodos de uso de inhibidor phosphoinositide 3-kinase
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
AR072227A1 (es) Derivados de triazinona sustituidos
NO20076254L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi

Legal Events

Date Code Title Description
FA Abandonment or withdrawal